CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro

Oncotarget

Volumn 7, Issue 21, 2016, Pages 30523-30535

  Hansen, Hinrich P ^a   Trad, Ahmad ^b   Dams, Maria ^a   Zigrino, Paola ^a   Moss, Marcia ^c   Tator, Maximilian ^a   Schön, Gisela ^a   Grenzi, Patricia C ^a   Bachurski, Daniel ^a   Aquino, Bruno ^d   Dürkop, Horst ^e   Reiners, Katrin S ^a   von Bergwelt Baildon, Michael ^a   Hallek, Michael ^a   Grötzinger, Joachim ^b   Engert, Andreas ^a   Paes Leme, Adriana F ^d   von Strandmann, Elke Pogge ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c BioZyme Inc   (United States)

^d BRAZILIAN CENTER FOR RESEARCH IN ENERGY AND MATERIALS CNPEM   (Brazil)

^e Pathodiagnostik Berlin   (Germany)

Author keywords

ADAM10; Brentuximab Vedotin; CD30; Extracellular vesicle; Hodgkin lymphoma

Indexed keywords

ADAM10 ENDOPEPTIDASE; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; ANTIBODY CONJUGATE; CD30 LIGAND; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 8;

ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER IMMUNOTHERAPY; CELL ADHESION; CELL MEDIATED CYTOTOXICITY; CELL VACUOLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INCUBATION TIME; MAST CELL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REED STERNBERG CELL; TUMOR MICROENVIRONMENT; BYSTANDER EFFECT; CELL COMMUNICATION; DRUG EFFECTS; EXOSOME; HODGKIN DISEASE; METABOLISM; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ADAM10 PROTEIN; BLOTTING, WESTERN; BYSTANDER EFFECT; CD30 LIGAND; CELL COMMUNICATION; CELL LINE, TUMOR; EXTRACELLULAR VESICLES; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; KI-1 ANTIGEN; TUMOR MICROENVIRONMENT;

EID: 84971529324     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8864     Document Type: Article

References (46)

1. Molin D, Edstrom A, Glimelius I, Glimelius B, Nilsson G, Sundstrom C, Enblad G. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol. 2002; 119:122-124
2. Molin D, Fischer M, Xiang Z, Larsson U, Harvima I, Venge P, Nilsson K, Sundstrom C, Enblad G, Nilsson G. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol. 2001; 114:616-623
3. Andersen MD, Kamper P, Nielsen PS, Bendix K, Riber-Hansen R, Steiniche T, Hamilton-Dutoit S, Clausen M, d'Amore F. Tumour-associated mast cells in classical Hodgkin's lymphoma: correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome. Eur J Haematol. 2016; 96:252-259
4. Enblad G, Sundstrom C, Glimelius B. Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematol Oncol. 1993; 11:187-193
5. Hansen HP, Engels HM, Dams M, Paes Leme AF, Pauletti BA, Simhadri VL, Durkop H, Reiners KS, Barnert S, Engert A, Schubert R, Quondamatteo F, Hallek M, et al. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma. J Pathol. 2014; 232:405-414
6. Josimovic-Alasevic O, Durkop H, Schwarting R, Backe E, Stein H, Diamantstein T. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol. 1989; 19:157-162
7. Eichenauer DA, Simhadri VL, Pogge v Strandmann E, Ludwig A, Matthews V, Reiners KS, Von Tresckow B, Saftig P, Rose-John S, Engert A, Hansen HP. ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro. Cancer Res. 2007; 67:332-338
8. Hansen HP, Dietrich S, Kisseleva T, Mokros T, Mentlein R, Lange HH, Murphy G, Lemke H. CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alphaconverting enzyme. J Immunol. 2000; 165:6703-6709
9. Folkesson M, Li C, Frebelius S, Swedenborg J, Wagsater D, Williams KJ, Eriksson P, Roy J, Liu ML. Proteolytically active ADAM10 and ADAM17 carried on membrane microvesicles in human abdominal aortic aneurysms. Thromb Haemost. 2015; 114
10. Aldinucci D, Celegato M, Casagrande N. Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance. Cancer Lett. 2015
11. Fischer M, Harvima IT, Carvalho RF, Moller C, Naukkarinen A, Enblad G, Nilsson G. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest. 2006; 116:2748-2756
12. Wiley SR, Goodwin RG, Smith CA. Reverse signaling via CD30 ligand. J Immunol. 1996; 157:3635-3639
13. Hargreaves PG, Al-Shamkhani A. Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30. Eur J Immunol. 2002; 32:163-173
14. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. Journal of clinical oncology. 2012; 30:2183-2189
15. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003; 102:1458-1465
16. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, Alley SC. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010; 16: 888-897
17. Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, Nicholas ND, Okeley NM, Lyon RP, Benjamin DR, Law CL. Intratumoral payload release influences the potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res. 2016. Epub ahead of print
18. Caescu CI, Jeschke GR, Turk BE. Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10. Biochem J. 2009; 424:79-88
19. Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, Kallen KJ, Rose-John S, Ludwig A. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood. 2003; 102:1186-1195
20. Froese P, Lemke H, Gerdes J, Havsteen B, Schwarting R, Hansen H, Stein H. Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines. J Immunol. 1987; 139:2081-2087
21. Horie R, Gattei V, Ito K, Imajo-Ohmi S, Tange T, Miyauchi J, Pinto A, Degan M, De Iuliis A, Tassan Mazzocco F, Rossi FM, Higashihara M, Watanabe T. Frequent expression of the variant CD30 in human malignant myeloid and lymphoid neoplasms. Am J Pathol. 1999; 155:2029-2041
22. Horie R, Ito K, Tatewaki M, Nagai M, Aizawa S, Higashihara M, Ishida T, Inoue J, Takizawa H, Watanabe T. A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages. Blood. 1996; 88:2422-2432
23. Lamparski HG, Metha-Damani A, Yao JY, Patel S, Hsu DH, Ruegg C, Le Pecq JB. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods. 2002; 270:211-226
24. Birgersdotter A, Baumforth KR, Porwit A, Sjoberg J, Wei W, Bjorkholm M, Murray PG, Ernberg I. Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma. Br J Cancer. 2009; 101:1393-1401
25. Yam LT, Li CY, Crosby WH. Cytochemical identification of monocytes and granulocytes. Am J Clin Pathol. 1971; 55:283-290
26. Pizzolo G, Vinante F, Chilosi M, Dallenbach F, Josimovic-Alasevic O, Diamantstein T, Stein H. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage. Br J Haematol. 1990; 75:282-284
27. Clape C, Fritz V, Henriquet C, Apparailly F, Fernandez PL, Iborra F, Avances C, Villalba M, Culine S, Fajas L. miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS One. 2009; 4:e7542
28. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, Garcia-Santos G, Ghajar C, Nitadori-Hoshino A, Hoffman C, Badal K, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012; 18:883-891
29. Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015; 527:329-335
30. Scheller J, Chalaris A, Garbers C, Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol. 2011; 32:380-387
31. Saftig P, Lichtenthaler SF. The alpha secretase ADAM10: A metalloprotease with multiple functions in the brain. Prog Neurobiol. 2015; 135:1-20
32. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nature reviews. 2009; 9:581-593
33. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT, Jr., Carter BS, Krichevsky AM, Breakefield XO. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature cell biology. 2008; 10: 1470-1476
34. Evans SM, Putt M, Yang XY, Lustig RA, Martinez-Lage M, Williams D, Desai A, Wolf R, Brem S, Koch CJ. Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients. J Neurooncol. 2016; 127:391-400
35. Friend C, Marovitz W, Henie G, Henie W, Tsuei D, Hirschhorn K, Holland JG, Cuttner J. Observations on cell lines derived from a patient with Hodgkin's disease. Cancer research. 1978; 38:2581-2591
36. Jones K, Nourse JP, Keane C, Bhatnagar A, Gandhi MK. Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res. 2014; 20:253-264
37. Matthey B, Borchmann P, Schnell R, Tawadros S, Lange H, Huhn M, Klimka A, Tur MK, Barth S, Engert A, Hansen HP. Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivo. Int J Cancer. 2004; 111: 568-574
38. Horn-Lohrens O, Tiemann M, Lange H, Kobarg J, Hafner M, Hansen H, Sterry W, Parwaresch RM, Lemke H. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer. 1995; 60:539-544
39. Mehta A, Forero-Torres A. Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma. Curr Oncol Rep. 2015; 17:41
40. Shimozato O, Takeda K, Yagita H, Okumura K. Expression of CD30 ligand (CD153) on murine activated T cells. Biochem Biophys Res Commun. 1999; 256:519-526
41. Cerutti A, Schaffer A, Goodwin RG, Shah S, Zan H, Ely S, Casali P. Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells. J Immunol. 2000; 165:786-794
42. Marinaccio C, Ingravallo G, Gaudio F, Perrone T, Nico B, Maoirano E, Specchia G, Ribatti D. Microvascular density, CD68 and tryptase expression in human diffuse large B-cell lymphoma. Leuk Res. 2014; 38:1374-1377
43. Roufosse F, Garaud S, de Leval L. Lymphoproliferative disorders associated with hypereosinophilia. Semin Hematol. 2012; 49:138-148
44. Hecht TT, Longo DL, Cossman J, Bolen JB, Hsu SM, Israel M, Fisher RI. Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells. Journal of immunology. 1985; 134:4231-4236
45. Schwarting R, Gerdes J, Durkop H, Falini B, Pileri S, Stein H. BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood. 1989; 74:1678-1689
46. Hansen HP, Recke A, Reineke U, Von Tresckow B, Borchmann P, Von Strandmann EP, Lange H, Lemke H, Engert A. The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5. Faseb J. 2004; 18:893-895